Phewas analysis revealed that targeting CSPG3 shares similar effects with targeting GCKR. Consequently, CSPG3 has emerged as a promising therapeutic target for HCC in the context of NAFLD and alcoholic cirrhosis, warranting further research to investigate its role in liver diseases. This evidence concerns the gene GCKR and liver disorder.